Application of trametes robiniophila particles in preparation of reagent for hepatocellular carcinoma TACE prognosis

Abstract

The invention provides an application of trametes robiniophila particles in preparation of a reagent for hepatocellular carcinoma TACE prognosis, and relates to the technical field of trametes robiniophila particle application, which comprises the following selection standards: (1) patients who are proved to be HCC through pathological examination or according with clinical diagnosis and are difficult to be subjected to operative treatment in clinical stages (the same-stage patients are selected as far as possible); (2) the age is more than 18 years old and less than 80 years old; (3) systemic treatment means such as surgical operation or chemical treatment, immunotherapy, targeted treatment and the like are not accepted as far as possible before entering the group; (4) the BCLC stage is A stage, B stage or C stage, but the C stage of the BCLC stage of the portal artery trunk cancer embolus is not selected; (5) the Child-Pugh score is less than or equal to 9; (6) ECOG score < = 2; the trametes robiniophila particles can effectively inhibit the growth of liver cancer cells, improve the quality of life of a patient suffering from the liver cancer after a radical operation, prolong the life of the patient, reduce the recurrence risk and the like, and solve the problem that the patient cannot tolerate subsequent TACE treatment due to the fact that the liver function and the immune function of the HCC patient are seriously damaged by repeated and large-scale embolism.

Description

technical field [0001] The invention relates to the technical field of application of Huaier granules, in particular to the application of Huaier granules in the preparation of reagents for TACE prognosis of hepatocellular carcinoma. Background technique [0002] Primary liver cancer is currently the fourth most common malignant tumor and the third leading cause of tumor death in my country, which seriously threatens the life and health of the Chinese people. Among them, hepatocellular carcinoma (HCC) accounts for more than 85%-90%. Chronic infection of HBV and HCV is an important reason for the occurrence of HCC, but effective antiviral therapy cannot completely prevent the occurrence of HCC. HCC has the characteristics of rapid progression, high postoperative recurrence and metastasis rate, and poor prognosis. Surgery is a radical treatment for HCC. The first choice for HCC, from irregular resection and primary lobectomy, to liver transplantation and quasi-hepatic resection,...

AI Technical Summary

Problems solved by technology

[0002] Primary liver cancer is currently the fourth most common malignant tumor and the third leading cause of tumor death in my country, which seriously threatens the life and health of our people, among which hepatocellular carcinoma (HCC) accounts for more than 85%-90%. Chronic infection of HBV and HCV is an important reason for the occurrence of HCC, but effective antiviral treatment cannot completely prevent the occurrence of HCC. HCC has the characteristics of rapid progression, high postoperative recurrence and metastasis rate, and poor prognosis. Surgical resection is the radical treatment for HCC. The first choice of treatment, from irregular resection and original lobe resection, gradually developed to liver transplantation and quasi-hepatectomy. After 1990, surgical treatment did not significantly prolong the survival of HCC patients, and the 5-year survival rate remained at 30%- 60%, and the recurrence rate was as high as 70%. Later, transarterial chemoembolization (TACE), radiofrequency ablation and other local treatment methods appeared successively, and TACE is the first choice for palliative treatment of unresectable HCC. There are some limitations that make its long-term efficacy unsatisfactory:

[0003] 1) After TACE, local ischemia and hypoxia in the cancer focus and adjacent tissues lead to increased levels of serum hypoxia-inducible factor (HIF) 1α and vascular endothelial growth factor (VEGF), and HIF-1α and VEGF stimulate HCC neogenesis Angiogenesis, resulting in the progression and metastasis of residual tumors;

[0004] 2) Repeated and large-scale embolization has seriously damaged the liver function and immune function of HCC patients, which may cause them to be unable to tolerate subsequent TACE treatment;

[0005] 3) The chemotherapy effect of HCC is poor;

[0006] Therefore, it is imperative to find an adjuvant drug with low toxicity and significant efficacy to make up for the insufficiency of TACE. The high recurrence and metastasis rate of liver cancer after TACE is still one of the major problems for clinicians. People are more and more aware of it. It is realized that local treatment is not once and for all, and effective systemic treatment is needed;

Images